FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer

Clinical Immunology

Volumn 131, Issue 1, 2009, Pages 1-10

  Rožková, Daniela ^a   Tišerová, Hana ^a   Fučíková, Jitka ^a   Lašt'ovička, Jan ^a   Podrazil, Michal ^a   Ulčová, Hana ^a   Budínský, Vít ^a   Prausová, Jana ^b   Linke, Zdeněk ^b   Minárik, Ivo ^a,b   Šedivá, Anna ^a   Špíšek, Radek ^a   Bartůňková, Jiřina ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cancer immunotherapy; ; Chemo immunotherapy; ; Dendritic cells; ; Prostate cancer; ; PSA

Indexed keywords

B7 ANTIGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CD4 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOCETAXEL; ERGOCALCIFEROL; GAMMA INTERFERON; GOSERELIN; HLA DR ANTIGEN; IMUKINE; INTERLEUKIN 2 RECEPTOR ALPHA; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SAMARIUM 153; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADVANCED CANCER; BONE METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNE RESPONSE; METASTASIS; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SHORT SURVEY; TREATMENT RESPONSE; TUMOR CELL;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 63449101031     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.01.001     Document Type: Short Survey

References (38)

1. Rozkova D., Horvath R., Bartunkova J., and Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin. Immunol. 120 3 (2006) 260-271
2. Sochorova K., Horvath R., Rozkova D., Litzman J., Bartunkova J., Sediva A., and Spisek R. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood 109 6 (2007) 2553-2556
3. Spisek R., Charalambous A., Mazumder A., Vesole D.H., Jagannath S., and Dhodapkar M.V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109 11 (2007) 4839-4845
4. Tobiasova Z., Pospisilova D., Miller A.M., Minarik I., Sochorova K., Spisek R., Rob L., and Bartunkova J. In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clin. Immunol. 122 1 (2007) 18-27
5. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 11 (2002) 991-998
6. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004) 329-360
7. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 2 (2004) 137-148
8. Ghiringhelli F., Puig P.E., Roux S., et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202 7 (2005) 919-929
9. Aspord C., Pedroza-Gonzalez A., Gallegos M., et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. 204 5 (2007) 1037-1047
10. Marincola F.M., Jaffee E.M., Hicklin D.J., and Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74 (2000) 181-273
11. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., and Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 7171 (2007) 903-907
12. Spisek R., Kukreja A., Chen L.C., et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J. Exp. Med. 204 4 (2007) 831-840
13. Dhodapkar M.V. Harnessing host immune responses to preneoplasia: promise and challenges. Cancer. Immunol. Immunother. 54 5 (2005) 409-413
14. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10 9 (2004) 909-915
15. Danna E.A., Sinha P., Gilbert M., Clements V.K., Pulaski B.A., and Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 64 6 (2004) 2205-2211
16. Zitvogel L., Apetoh L., Ghiringhelli F., Andre F., Tesniere A., and Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 118 6 (2008) 1991-2001
17. Zitvogel L., Apetoh L., Ghiringhelli F., and Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8 1 (2008) 59-73
18. Spisek R., and Dhodapkar M.V. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 6 16 (2007) 1962-1965
19. Casares N., Pequignot M.O., Tesniere A., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202 12 (2005) 1691-1701
20. Chaput N., De Botton S., Obeid M., et al. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J. Mol. Med. 85 10 (2007) 1069-1076
21. Obeid M., Tesniere A., Ghiringhelli F., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 1 (2007) 54-61
22. Obeid M., Tesniere A., Panaretakis T., et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol. Rev. 220 (2007) 22-34
23. Antonia S.J., Mirza N., Fricke I., et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12 3 Pt. 1 (2006) 878-887
24. Yu J.S., Wheeler C.J., Zeltzer P.M., et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61 3 (2001) 842-847
25. Wheeler C.J., Das A., Liu G., Yu J.S., and Black K.L. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10 16 (2004) 5316-5326
26. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 9 (2007) 1050-1059
27. Bushley A.W., Ferrell R., McDuffie K., et al. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol. Oncol. 95 3 (2004) 672-679
28. Lech-Maranda E., Baseggio L., Bienvenu J., et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103 9 (2004) 3529-3534
29. Spisek R., and Dhodapkar M.V. Immunoprevention of cancer. Hematol. Oncol. Clin. North Am. 20 3 (2006) 735-750
30. Kiessling A., Fussel S., Wehner R., Bachmann M., Wirth M.P., Rieber E.P., and Schmitz M. Advances in specific immunotherapy for prostate cancer. Eur. Urol. 53 4 (2008) 694-708
31. Thomas-Kaskel A.K., Waller C.F., Schultze-Seemann W., and Veelken H. Immunotherapy with dendritic cells for prostate cancer. Int. J. Cancer 121 3 (2007) 467-473
32. Miller A.M., and Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol. Immunother. 56 1 (2007) 81-87
33. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 9 (2004) 942-949
34. Ghiringhelli F., Menard C., Puig P.E., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56 5 (2007) 641-648
35. Berard F., Blanco P., Davoust J., et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192 11 (2000) 1535-1544
36. Nouri-Shirazi M., Banchereau J., Bell D., Burkeholder S., Kraus E.T., Davoust J., and Palucka K.A. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J. Immunol. 165 7 (2000) 3797-3803
37. Spisek R., Chevallier P., Morineau N., Milpied N., Avet-Loiseau H., Harousseau J.L., Meflah K., and Gregoire M. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 62 10 (2002) 2861-2868
38. Arlen P.M., Gulley J.L., Parker C., et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12 4 (2006) 1260-1269